Bibliography
- WOOD PL, HAWKINSON JE: N-Methyl-n-aspartate an-tagonists for stroke and head trauma. Exp. Opin. Invest. Drugs (1997) 6:389–397.
- SVEINBJORNSDOTTIR S, SANDER JW, UPTON D eta].: The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. (1993) 16:165–174.
- ROCKSTROH S, EMRE M, TARRAL A, POKORNY R: Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans. Psychopharma-cology (1996) 124:261–266.
- GREENE JG, PORTER RHP, GREENAMYRE JT: ARL-15896, a novel N-methyl-n-aspartate receptor ion channel an-tagonist: neuroprotection against mitochondrial metabolic toxicity and regional pharmacology. Exp. Neurology (1996) 137:66–72.
- BELAYEV L, BUSTO R, ZHAO W, GINSBERG MD: HU-211, a novel noncompetitive N-methyl-D-aspartate antago-nist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke (1995) 26:2313–2319.
- ESHHAR N, STRIEM S, KOHEN R, TIROSH 0, BIEGON A: Neuroprotective and anti-oxidant activities of HU-211, a novel NMDA receptor antagonist. Eur. J. Pharmacol (1995) 283:19–30.
- MENNITTI F, CHENARD B, COLLINS M et al: CP-101,606, a potent neuroprotectant selective for forebrain neu-rons. Eur.J. Pharmacol (1997) 331:117–126.
- TSUCHIDA E, RICE M, BULLOCK R: The neuroprotective effect of the forebrain-selective NMDA antagonist CP101,606 upon focal ischemic brain damage caused by acute subdural hematoma in the rat. J. Neurotrauma (1997) 14:409–417.
- OKIYAMA K, SMITH DH, WHITE WF, RICHTER K, MCIN-TOSH TK: Effects of the novel NMDA antagonists CP-98,113, CP-101,581 and CP-101,606 on cognitive func-tion and regional cerebral edema following experi-mental brain injury in the rat. J. Neurotrauma (1997) 14:211–222.
- FISCHER G, MUTEL V, TRUBE G et al.: RO 25-6981, ahighly potent and selective blocker of N-methyl-n-a-spartate receptors containing the NR2B subunit - char-acterization in vitro. J. Pharmacol. Exp. Ther. (1997) 283:1285–1292.
- PIETRA C, ZIVIANI L, VALERIO E, TARTER G, REGGIANI A: Neuroprotection by GV150526A: a comparison with reference compounds. Stroke (1996) 27. Abstract 130.
- MENNINI T, MANCINI L, REGGIANI A, TRIST D: GV 150526a, 7-cl-kynurenic acid and 11A966 antagonize the glycine enhancement of N-methyl-o-aspartate--induced [H-3]noradrenaline and [H-3]dopamine re-lease. Eur. J. Pharmacol. (1997) 336:275–281.
- WARNER DS, MARTIN H, LUDWIG P et al.: In vivo models of cerebral ischemia: effects of parenternally adminis-tered NMDA receptor glycine site antagonists. J. Cereb. Blood Flow Metab. (1995) 15:188–196.